| 摘要 |
Apolipoprotein A-I-rich Lhigh-density Lipoprotein 2 (HDL2) and Apolipoprotein A-I (ApoA-I) was discovered to inhibit angiogenesis in an in vitro human angiogenesis model, the human placental vein angiogenesis model. Apolipoprotein A-I was able to destroy a pre-existing angiogenic response as well as prevent the development of new vessels. Application of Apolipoprotein A-I will be effective in inhibiting tumor growth dependent on angiogenesis, and in decreasing existing blood vessels formed by tumors. It will also be effective in treating non-cancerous diseases which symptoms include an increase in angiogenesis, e.g., psoriasis, retinopathy of prematurity, neovascular glaucoma, diabetic retinopathy, obesity, and psoriasis.
|
